The Journal of Rheumatology

VOLUME 42: NO. 12 jrheum.org DECEMBER 2015

Editorials

Can Methotrexate Prevent Knee Arthroplasties in Patients with Rheumatoid Arthritis? *J.M. Kremer* 2217

The Difficult Task of Assessing Psoriatic Arthritis *A. Cauli, M. Piga* 2219

Articles

A Study of Multiple Causes of Death in RA *F.A. Pinheiro, D.C. Souza, E.I. Sato* 2221

The Risk of TB in Patients with RA Treated with TNF-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies *J.W. Ai, S. Zhang, Q.L. Ruan, et al* 2229

Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with RA in Remission: A CORRONA and NinJa Collaborative Cohort Study *K. Yoshida, H. Radner, M.D. Mjaavatten, et al* 2238

RA: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden *A.B. Pedersen, A. Mor, F. Mehnert, R.W. Thomsen, S.P. Johnsen, M. Nørgaard* 2247

Concomitant MTX Protects Against TKA in Patients with RA Treated with TNF Inhibitors *S. Asai, N. Takahashi, K. Funahashi, et al* 2255

Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in RA: A Systematic Review and Metaanalysis *C. Vidal, T. Barnetche, J. Morel, B. Combe, C. Daïen* . . .2261

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol *M.E. Clowse, D.C. Wolf, F. Förger, et al* 2270

Clinical and Radiographic Outcomes in Patients Diagnosed with Early RA in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study *G. Haugeberg, P. Bøyesen, K. Helgetveit, A. Prøven* 2279

Safety and Efficacy of Belimumab to Treat SLE in Academic Clinical Practices *J.S. Hui-Yuen, A. Reddy, J. Taylor, et al* 2288

A Multicenter Study of Invasive Fungal Infections in Patients with Childhood-onset SLE *M.F. Silva, M.P. Ferriani, M.T. Terreri, et al* 2296

Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset SLE *Y. Yang, S. Kumar, L.S. Lim, E.D. Silverman, D.M. Levy* 2304

Nighttime Blood Pressure Patterns and Subclinical Atherosclerosis in Women with SLE *J.M. Sabio, J. Martinez-Bordonado, I. Sánchez-Berná, et al* 2310

Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent SLE *A.J. Steiman, D.D. Gladman, D. Ibañez, et al* 2318

Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort *L. Sáez-Comet, C.P. Simeón-Aznar, M. Pérez-Conesa, et al, and the RESCLE Investigators* . . .2327

Patient's Global Assessment as an Outcome Measure for PsA in Clinical Practice: A Surrogate for Measuring Low Disease Activity? *E. Lubrano, F.M. Perrotta, W.J. Parsons, A. Marchesoni* 2332

Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study *A.V. Heinonen, K.J. Aaltonen, J.T. Joensuu, et al* 2339

Effects of Aerobic Training in Patients with Ankylosing Spondylitis *F. Jennings, H.A. Oliveira, M.C. Souza, V.G. Cruz, J. Natour* 2347

Fatigue in Ankylosing Spondylitis and Nonradiographic AxSpA: Analysis from a Longitudinal Observation Cohort *M. Bedaiwi, I. Sari, A. Thavaneswaran, R. Ayearst, N. Haroon, R.D. Inman* 2354

Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in AxSpA *M. Dougados, E. Wood, L. Gossec, A. Dubanchet, I. Logeart, D. van der Heijde* 2361

Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls *S. van Genderen, A. Boonen, D. van der Heijde, et al* 2369

TNF-α Inhibition in Ankylosing Spondylitis and Nonradiographic AxSpA: Treatment Response, Drug Survival, and Patient Outcome *J. Corli, R. Flipo, P. Philippe, et al* 2376

Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the USA *K. Raimundo, A.M. Farr, G. Kim, G. Duna* 2383

Free online via JRheum Full Release option

Contents continued on page xx

PRINTED IN CANADA – ISSN 0315-162X

Downloaded on September 15, 2026 from www.jrheum.org

Native Joint Septic Arthritis: Epidemiology, Clinical Features, and Microbiological Causes in a New Zealand Population *N. Kennedy, S.T. Chambers, I. Nolan, et al* . .2392

Knee Pain Patterns and Associations with Pain and Function in Persons with or at Risk for Symptomatic Radiographic OA: A Cross-sectional Analysis *D.L. Riddle, M. Makowski* 2398

Evaluating Disease Severity in Chronic Pain Patients with and without FM: A Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale *R. Friend, R.M. Bennett* 2404

Pediatric Rheumatology

Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with JDM *N. Kobayashi, I. Kobayashi, M. Mori, et al* 2412

Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls *H. Schmeling, M. Mahler, D.M. Levy, et al* 2419

Psychiatric Disorders in Young Adults Diagnosed with Juvenile FM in Adolescence *N.R. Cunningham, S.T. Tran, A.M. Lynch-Jordan, et al* . .2427

Images in Rheumatology

Maffucci Syndrome *Y.P. Tsao, C.Y. Tsai, W.S. Chen* . . .2434

OMERACT 12 — International Consensus Conference on Outcome Measures in Rheumatology, Budapest, Hungary, May 7-11, 2014

Special Interest Groups I

Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014 *G. Hatemi, Y. Ozguler, H. Direskeneli, et al* 2436

Development of a Draft Core Set of Domains for Measuring Shared Decision Making in OA: An OMERACT Working Group on Shared Decision Making *K. Toupin-April, J. Barton, L. Fraenkel, et al* 2442

Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures *J. Petkovic, J. Epstein, R. Buchbinder, et al* . .2448

Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group *R. Grainger, N. Dalbeth, H. Keen, et al* 2460

Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12 *S.Z. Aydin, H. Direskeneli, A. Sreih, et al* 2465

The OMERACT MRI in Arthritis Working Group — Update on Status and Future Research Priorities *M. Østergaard, P. Bird, F. Gandjbakhch, et al* 2470

Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial *D. Glinatsi, P. Bird, F. Gandjbakhch, et al* 2473

Validation of the OMERACT MRI Joint Space Narrowing Score for the Wrist in a Multireader Longitudinal Trial *D. Glinatsi, S. Lillegraven, E.A. Haavardsholm, et al* . . .2480

The Longitudinal Reliability and Responsiveness of the OMERACT Hand OA MRI Scoring System (HOAMRIS) *I.K. Haugen, I. Eshed, F. Gandjbakhch, et al* 2486

Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure — Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12 *M. Regardt, P. Basharat, L. Christopher-Stine, et al* 2492

Outcome Domains and Measures in TJR Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative *J.A. Singh, M. Dohm, A.P. Sprowson, et al* 2496

Outcome Measures in Polymyalgia Rheumatica. A Systematic Review *C. Duarte, R.J. Ferreira, S.L. Mackie, J.R. Kirwan, J.A. Pereira de Silva, on behalf of the OMERACT Polymyalgia Rheumatica Special Interest Group* 2503

Correspondence

Specificity of Systemic Sclerosis Classification Criteria *M. Baron, J.E. Pope, F. van den Hoogen, et al* 2512

Reply *A.M. Hoffmann-Vold* 2513

On the Relationship of Male Sexual Dysfunction and Ankylosing Spondylitis *Y.F. Liu, C.Y. Wen, S.H. Tu* 2513

Reply *D. Fan, L. Xin, L. Liu, G. Cai, S. Xu, F. Pan* 2514

Letter

Diagnostic Challenges of SAPHO Syndrome *M. Colina* 2514

Reviewer Index 2516

Content Index 2518

Meetings in Rheumatology x

Downloaded on September 15, 2026 from www.jrheum.org